Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?

Johnson & Johnson JNJ, under its Innovative Medicine segment, markets several multi-million-dollar drugs that cover a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology, oncology, pulmonary arterial hypertension (PAH) and infectious diseases. J&J is scheduled to report second-quarter results on July 16 and investors will be keen...